Results 291 to 300 of about 12,265,574 (365)

Change in body mass index and disease burden among people with obesity and multiple long‐term conditions

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Obesity is a risk factor for multiple long‐term conditions (MLTCs/multimorbidity). However, the impact of weight loss in people with MLTCs is unclear. We investigated the association between body mass index (BMI) change and the development of obesity‐related complications (ORCs), as well as clinical and economic outcomes in individuals ...
Kamlesh Khunti   +6 more
wiley   +1 more source

Antihypertensive treatment and risk of atrial fibrillation: a nationwide study.

open access: yesEuropean Heart Journal, 2014
S. Marott   +3 more
semanticscholar   +1 more source

Association of metabolic obesity phenotypes with cognitive decline in the ELSA‐Brasil study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To investigate the association between metabolic obesity phenotypes and cognitive decline and evaluate the potential mediating role of C‐reactive protein (CRP). Methods Longitudinal cohort study using three waves (2008–2019) of the Brazilian Longitudinal Study of Adult Health (ELSA‐Brasil).
Paulo Henrique Lazzaris Coelho   +9 more
wiley   +1 more source

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki   +3 more
wiley   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami   +16 more
wiley   +1 more source

Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient. [PDF]

open access: yesInflammopharmacology
García-Álvarez RM   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy